Vaccine maker Serum Institute of India (SII) is hopeful of developing a COVID-19 vaccine by the year-end as it is focusing on a “good and safe” product and is not in a “rush”.
Replying to a question about the development of the COVID-19 vaccine, Adar Poonawalla, CEO of SII, said that by the end of 2020, the SII is hoping to have a vaccine.
He was speaking during the launch of ‘Compact XL, a compact diagnostics machine by MyLab Discovery Solutions, that will automate lab processes from sample handling to preparing RT-PCR tubes.
“End of the year, we are hoping to have a vaccine. So we will discuss once of the phase three trials for the product come about. Recently, there was news about another vaccine candidate which was being rushed. We do not want to rush anything. We want to emphasis on safety and efficacy… and once we are confident of good and safe vaccine, we will announce but that is still six months away from now,” said Adar.
He further said that till the vaccine comes, testing is the key and that is why SII has invested in MyLabs.
“If you test, isolate and segregate, we can manage the situation till the good cure or vaccine comes around,” said Adar.
SII has invested over Rs 100 crore in MyLabs, a Pune-based molecular diagnostics firm.
Poonawalla lamented that India is not testing enough and added that Indian test manufacturers including MyLabs are picking up the production capacity.
“There is a fear that what will happen if the number of positive patients increases. I would like to say that there is no harm if the number increases as it will help us detect people,” he added.
Poonawalla also sought permission to allow export of the test kits.
“We have enough capacity in manufacturing testing kits. MyLab can produce 2 million kits per week and there is no that much demand in India so allow us to export and we have enough buffer stock for India readily available if there is more outbreak,” he said adding they are waiting for the government’s blessings.